Tag Archives: Glioblastoma Multiforme

May, 2017

February, 2017

  • 7 February

    GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

    London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …

October, 2016

  • 31 October

    Roche Licenses its PI3K Pathway Brain Cancer Drug to Novogen

    SYDNEY, Oct. 30, 2016 /PRNewswire/ — Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway. The …

July, 2016

March, 2016

  • 7 March

    Celldex Discontinues its Late-Stage Brain Cancer Vaccine Study

    HAMPTON, N.J., March 07, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma …